Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 6/20 | 0.45 |
| ▸ | FPR2 | P25090 | 5/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21262639 | 1.00 | MTOR (0.45) | MTORFPR2PDK1PDK2PDK3 | |
| SCHEMBL22556089 | 1.00 | MTOR (0.45) | MTORFPR2PDK1PDK2PDK3 | |
| SCHEMBL22556145 | 0.87 | MTOR (0.45) | MTORFPR2PIK3CAATRAURKA | |
| SCHEMBL22556144 | 0.87 | MTOR (0.45) | MTORFPR2PIK3CAATRAURKA | |
| SCHEMBL21262225 | 0.85 | FPR2 (0.44) | MTORFPR2PIK3CAATRAURKA | |
| SCHEMBL22569553 | 0.81 | MTOR (0.35) | MTORFPR2PIK3CAATRAURKA | |
| SCHEMBL22569432 | 0.81 | MTOR (0.35) | MTORFPR2PIK3CAATRAURKA | |
| SCHEMBL21262098 | 0.80 | ATR (0.47) | MTORPIK3CDPIK3CGPIK3CAATR | |
| SCHEMBL22556125 | 0.80 | ATR (0.47) | MTORPIK3CDPIK3CGPIK3CAATR | |
| SCHEMBL21262100 | 0.80 | ATR (0.47) | MTORPIK3CDPIK3CGPIK3CAATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| EP-3749672-B1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2022-07-27 | — | — | EP | disclosed |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-10-22 | — | — | US | disclosed |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-10-22 | — | — | US | disclosed |
| WO-2019153080-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | BCL6, BCL6B, BCL3 | MTOR 2064/4885FPR2 4516/4885PDK1 869/4885 |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | BCL6, BCL6B, BCL3 | MTOR 2027/4885FPR2 4485/4885PDK1 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.